HK1203149A1 - Novel dosage form and formulation of abediterol - Google Patents

Novel dosage form and formulation of abediterol Download PDF

Info

Publication number
HK1203149A1
HK1203149A1 HK15103713.3A HK15103713A HK1203149A1 HK 1203149 A1 HK1203149 A1 HK 1203149A1 HK 15103713 A HK15103713 A HK 15103713A HK 1203149 A1 HK1203149 A1 HK 1203149A1
Authority
HK
Hong Kong
Prior art keywords
abediterol
formulation
dosage form
inhalation
pharmaceutically acceptable
Prior art date
Application number
HK15103713.3A
Other languages
English (en)
Chinese (zh)
Inventor
Sandrine Allain Ruiz
Beatriz SEOANE NUNEZ
Gonzalo De Miquel Serra
Original Assignee
Almirall S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46317311&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1203149(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall S.A. filed Critical Almirall S.A.
Publication of HK1203149A1 publication Critical patent/HK1203149A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
HK15103713.3A 2012-05-31 2013-05-30 Novel dosage form and formulation of abediterol HK1203149A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12382221.5 2012-05-31
EP12382221.5A EP2668941A1 (en) 2012-05-31 2012-05-31 Novel dosage form and formulation of abediterol
US201261660003P 2012-06-15 2012-06-15
US61/660,003 2012-06-15
PCT/EP2013/061181 WO2013178742A1 (en) 2012-05-31 2013-05-30 Novel dosage form and formulation of abediterol

Publications (1)

Publication Number Publication Date
HK1203149A1 true HK1203149A1 (en) 2015-10-23

Family

ID=46317311

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15103713.3A HK1203149A1 (en) 2012-05-31 2013-05-30 Novel dosage form and formulation of abediterol

Country Status (29)

Country Link
US (2) US20150140099A1 (enExample)
EP (2) EP2668941A1 (enExample)
JP (1) JP6272836B2 (enExample)
KR (2) KR20180104197A (enExample)
CN (1) CN104394852A (enExample)
AR (1) AR091233A1 (enExample)
AU (1) AU2013269565B2 (enExample)
BR (1) BR112014029735A2 (enExample)
CA (1) CA2871358C (enExample)
CL (1) CL2014003286A1 (enExample)
CO (1) CO7141434A2 (enExample)
CR (1) CR20140540A (enExample)
DO (1) DOP2014000271A (enExample)
EA (1) EA201401354A1 (enExample)
EC (1) ECSP14028814A (enExample)
HK (1) HK1203149A1 (enExample)
IL (1) IL235831B (enExample)
IN (1) IN2014DN08672A (enExample)
MX (1) MX2014014350A (enExample)
MY (1) MY184654A (enExample)
NI (1) NI201400139A (enExample)
NZ (1) NZ701261A (enExample)
PE (1) PE20150171A1 (enExample)
PH (1) PH12014502662A1 (enExample)
SG (3) SG11201407110QA (enExample)
TW (1) TWI610690B (enExample)
UY (1) UY34838A (enExample)
WO (1) WO2013178742A1 (enExample)
ZA (1) ZA201407405B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
US20150224197A1 (en) * 2012-07-05 2015-08-13 Arven Ilac Sanayi Ve Ticaret A.S. Inhalation compositions
WO2015193631A1 (en) * 2014-06-18 2015-12-23 Cipla Limited Pharmaceutical composition comprising a beta-2-agonist and anticholinergic agent
WO2019142214A1 (en) * 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
ES2964913T3 (es) 2018-05-22 2024-04-10 Bard Inc C R Sistema de cateterización
EP4614117A3 (en) 2018-08-10 2025-10-22 C. R. Bard, Inc. Automated urine-output-measurement systems and methods thereof
US12083261B2 (en) 2020-06-05 2024-09-10 C. R. Bard, Inc. Automated fluid output monitoring
US12055249B2 (en) 2020-07-21 2024-08-06 C. R. Bard, Inc. Automatic fluid flow system with retractable connection
US12408853B2 (en) 2020-12-17 2025-09-09 C. R. Bard, Inc. Smart bag to measure urine output via catheter
US12364423B2 (en) 2020-12-21 2025-07-22 C. R. Bard, Inc. Automated urinary output-measuring systems and methods
US11931151B2 (en) 2020-12-22 2024-03-19 C. R. Bard, Inc. Automated urinary output measuring system
US12246146B2 (en) 2020-12-23 2025-03-11 C. R. Bard, Inc. Automated weight based fluid output monitoring system
US12446813B2 (en) 2021-08-23 2025-10-21 C. R. Bard, Inc. Automated urine output system for attachment to hospital bed
WO2025151671A1 (en) * 2024-01-12 2025-07-17 Texas Tech University System Compositions and methods for treating diet-induced obesity and associated metabolic disorders

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT7920688U1 (it) 1979-02-05 1980-08-05 Chiesi Paolo Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore
ATE23272T1 (de) 1981-07-08 1986-11-15 Draco Ab Pulverinhalator.
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
ES2113889T3 (es) 1990-09-26 1998-05-16 Pharmachemie Bv Dispositivos inhaladores provistos de un deposito para varias dosis de producto de inhalacion, dispositivo de transporte y camaras de turbulencia.
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
CA2152088C (en) 1992-12-18 1999-12-07 Thomas J. Ambrosio Inhaler for powdered medications
CN1325129C (zh) 1995-06-21 2007-07-11 Meda制药有限及两合公司 带整体计量装置的药筒和药粉吸入器
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
ITMI20010357U1 (it) 2001-06-28 2002-12-30 Plastiape Spa Dispositivo inalatore
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
CA2540005A1 (en) * 2003-09-26 2005-04-07 Schering Corporation Pulmonary disease treatment
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
AU2005263486B2 (en) 2004-07-16 2011-05-12 Astrazeneca Ab Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
EP2100598A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2221297A1 (en) * 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases
EP2221055A1 (en) * 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function

Also Published As

Publication number Publication date
AU2013269565B2 (en) 2017-07-20
ECSP14028814A (es) 2015-12-31
EP2854771A1 (en) 2015-04-08
TW201347789A (zh) 2013-12-01
CA2871358C (en) 2020-09-29
MY184654A (en) 2021-04-14
SG11201407110QA (en) 2014-12-30
DOP2014000271A (es) 2015-02-27
ZA201407405B (en) 2015-11-25
PE20150171A1 (es) 2015-01-31
CL2014003286A1 (es) 2015-02-20
CN104394852A (zh) 2015-03-04
IN2014DN08672A (enExample) 2015-05-22
PH12014502662A1 (en) 2015-02-02
MX2014014350A (es) 2015-03-03
CO7141434A2 (es) 2014-12-12
JP6272836B2 (ja) 2018-01-31
NI201400139A (es) 2015-12-10
TWI610690B (zh) 2018-01-11
IL235831A0 (en) 2015-01-29
WO2013178742A1 (en) 2013-12-05
KR20150018526A (ko) 2015-02-23
NZ701261A (en) 2016-08-26
EA201401354A1 (ru) 2015-05-29
JP2015519356A (ja) 2015-07-09
KR20180104197A (ko) 2018-09-19
SG10201913424SA (en) 2020-03-30
IL235831B (en) 2020-09-30
BR112014029735A2 (pt) 2017-06-27
AU2013269565A1 (en) 2014-10-30
SG10201609119VA (en) 2016-12-29
US20160303108A1 (en) 2016-10-20
CR20140540A (es) 2015-01-16
CA2871358A1 (en) 2013-12-05
UY34838A (es) 2014-03-31
AR091233A1 (es) 2015-01-21
US20150140099A1 (en) 2015-05-21
EP2668941A1 (en) 2013-12-04

Similar Documents

Publication Publication Date Title
HK1203149A1 (en) Novel dosage form and formulation of abediterol
UA101653C2 (uk) Композиція для інгаляції, що містить аклідиній для лікування астми та хронічного обструктивного захворювання легень
UA101652C2 (uk) Композиція для інгаляції, що містить аклідиній для лікування астми та хронічного обструктивного захворювання легень
MY179703A (en) Dry powder formulation comprising a phosphodiesterase inhibitor
AR067639A1 (es) Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente
WO2013021199A3 (en) Eutectic mixture for pulmonary administration
UA107499C2 (uk) Склад сухого порошку, який містить антимускариновий засіб
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
JP2015519356A5 (enExample)
EP2682108A3 (en) Dry Powder Inhalers Comprising a Carrier Other Than Lactose and a Ternary Component
EP2682097A3 (en) Dry Powder Inhalers Comprising A Carrier Other Than Lactose
MX2015015132A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
MD20140131A2 (ro) Doză şi formă preparativă nouă pentru inhalare care cuprinde aclidiniu
HK1215167A1 (zh) 可吸入药用组合物和含有该药用组合物的吸入器装置
MY187442A (en) A pharmaceutical composition containing budesonide and formoterol
UA115989C2 (uk) Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії
JP2013522295A5 (enExample)
MY191295A (en) Pharmaceutical composition containing budesonide and formoterol
WO2019098969A3 (en) Dry powder compositions for inhalation
TN2013000015A1 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
TH1401007107A (th) รูปฟอร์มขนาดใช้ยา และ สูตรผสมใหม่ของเอบีไดเทอรอล
GR1008468B (el) Μιγμα σισπλατινης σε μορφη λεπτοκοκκης εισπνεομενης ξηρας σκονης